Regenacy names new President and CEO

pharmafile | June 28, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Regenacy, appointment 

Simon S Jones has been revealed as the new President and Chief Executive Officer of Regenacy Pharmaceuticals, a biopharma company specialising in selective protein acetylation. The previous figure in the role, Walter Ogier, will continue to serve Regenacy on its board.

Regenacy began in December 2016 as a spin-out from Acetylon Pharmaceuticals, which Jones has worked with since 2009. Throughout his career, he has held senior positions in drug discovery and preclinical development at companies including Genetics Institute/Wyeth – acquired by Pfizer in 2009 – Creative BioMolecules, Curis, and ArQule. Prior to joining Acetylon, he worked as Vice President of Biology and ADMET at EPIX Pharmaceuticals.

In his time at Acetylon, Jones has served as Chief Operating Officer and Senior Vice President, Clinical Development, leading the research and development of the company’s HDAC inhibitors.

“Simon’s extensive research and drug development experience will continue to drive our ongoing efforts to develop selective HDAC inhibitors for the treatment of peripheral neuropathies, ciliopathic/polycystic diseases, haemoglobinopathies, cognitive disorders and oncology indications,” commented Marc Cohen, Co-Founder and Executive Chairman of Regenacy. “We are very pleased to welcome Simon into his new role as President and Chief Executive Officer at Regenacy. We would also like to extend a sincere thank you to Walter for his leadership and significant contributions in building Acetylon, orchestrating Acetylon’s acquisition by Celgene, and launching Regenacy. We look forward to Walter’s continued involvement with Regenacy as he transitions to an advisory phase of his career.”

Jones himself remarked: “Regenacy has a tremendous opportunity to further the development of ricolinostat into Phase 2 clinical trials in peripheral neuropathy and ciliopathic diseases and development of HDAC1, 2 inhibitors to treat blood and other disorders. It is an honour to assume the role as President and Chief Executive Officer and to have the opportunity to continue working with the incredible team at Regenacy.”

Related Content


Myeloma UK reveals new Director of Research appointment

UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …


Abbott CEO to step down after 21 years

After more than two decades at the head of the company, it has emerged that …


Lonza CEO to step down in 2020

It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to …

Latest content